{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T16:25:06Z","timestamp":1749831906172},"reference-count":260,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,18]]},"DOI":"10.7759\/cureus.43725","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T04:52:37Z","timestamp":1692420757000},"source":"Crossref","is-referenced-by-count":2,"title":["A Comprehensive Literature Review on Managing Systemic Lupus Erythematosus: Addressing Cardiovascular Disease Risk in Females and Its Autoimmune Disease Associations"],"prefix":"10.7759","author":[{"given":"Saleha","family":"Dar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Koirala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arooba","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounika Deepthi","family":"Bellary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arya V","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bejoi","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahida","family":"Baigam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Razzaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zain U","family":"Abdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzzam Ahmed","family":"Khawaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20683","article-title":"Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality","volume":"64","author":"Jakes RW","year":"2012","unstructured":"Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012, 64:159-68. 10.1002\/acr.20683","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref2","article-title":"Manifestations of systemic lupus erythematosus","volume":"6","author":"Cojocaru M","year":"2011","unstructured":"Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011, 6:330-6.","journal-title":"Maedica (Bucur)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e3181e8138e","article-title":"Review article: systemic lupus erythematosus: a review for anesthesiologists","volume":"111","author":"Ben-Menachem E","year":"2010","unstructured":"Ben-Menachem E. Review article: systemic lupus erythematosus: a review for anesthesiologists. Anesth Analg. 2010, 111:665-76. 10.1213\/ANE.0b013e3181e8138e","journal-title":"Anesth Analg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp038168","article-title":"Systemic lupus erythematosus and accelerated atherosclerosis","volume":"349","author":"Hahn BH","year":"2003","unstructured":"Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med. 2003, 349:2379-80. 10.1056\/NEJMp038168","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2007.01.003","article-title":"Monitoring systemic lupus erythematosus in standard clinical care","volume":"21","author":"Petri M","year":"2007","unstructured":"Petri M. Monitoring systemic lupus erythematosus in standard clinical care. Best Pract Res Clin Rheumatol. 2007, 21:687-97. 10.1016\/j.berh.2007.01.003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu2021oa","article-title":"Musculoskeletal involvement in systemic lupus erythematosus","volume":"13","author":"Zoma A","year":"2004","unstructured":"Zoma A. Musculoskeletal involvement in systemic lupus erythematosus. Lupus. 2004, 13:851-3. 10.1191\/0961203303lu2021oa","journal-title":"Lupus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.22578","article-title":"Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus","volume":"56","author":"Nzeusseu Toukap A","year":"2007","unstructured":"Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ, Houssiau FA, Lauwerys BR. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum. 2007, 56:1579-88. 10.1002\/art.22578","journal-title":"Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera R","year":"2003","unstructured":"Cervera R, Khamashta MA, Font J, et al.. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003, 82:299-308. 10.1097\/01.md.0000091181.93122.55","journal-title":"Medicine (Baltimore)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60279-7","article-title":"Systemic lupus erythematosus","volume":"369","author":"D\u2019Cruz DP","year":"2007","unstructured":"D\u2019Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007, 369:587-96. 10.1016\/S0140-6736(07)60279-7","journal-title":"Lancet"},{"key":"ref10","article-title":"Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies","volume":"31","author":"D\u2019Cruz DP","year":"2004","unstructured":"D\u2019Cruz DP, Mellor-Pita S, Joven B, et al.. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol. 2004, 31:280-5.","journal-title":"J Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000267320.48939.d0","article-title":"CNS lupus: a study of 41 patients","volume":"69","author":"Joseph FG","year":"2007","unstructured":"Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology. 2007, 69:644-54. 10.1212\/01.wnl.0000267320.48939.d0","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200212000-00011","article-title":"Ocular manifestations of systemic lupus erythematosus","volume":"13","author":"Arevalo JF","year":"2002","unstructured":"Arevalo JF, Lowder CY, Muci-Mendoza R. Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol. 2002, 13:404-10. 10.1097\/00055735-200212000-00011","journal-title":"Curr Opin Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2250rr","article-title":"Ocular manifestations of systemic lupus erythematosus: a clinical review","volume":"15","author":"Peponis V","year":"2006","unstructured":"Peponis V, Kyttaris VC, Tyradellis C, Vergados I, Sitaras NM. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus. 2006, 15:3-12. 10.1191\/0961203306lu2250rr","journal-title":"Lupus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.76a.gr005","article-title":"Lupus update: perspective and clinical pearls","volume":"76","author":"Manzi S","year":"2009","unstructured":"Manzi S. Lupus update: perspective and clinical pearls. Cleve Clin J Med. 2009, 76:137-42. 10.3949\/ccjm.76a.gr005","journal-title":"Cleve Clin J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016105","article-title":"Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures","volume":"63","author":"Sangle S","year":"2004","unstructured":"Sangle S, D'Cruz DP, Khamashta MA, Hughes GR. Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures. Ann Rheum Dis. 2004, 63:1241-3. 10.1136\/ard.2003.016105","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem105","article-title":"Prevalence and risk factors of osteoporosis in female SLE patients-extended report","volume":"46","author":"Almehed K","year":"2007","unstructured":"Almehed K, Forsblad d'Elia H, Kvist G, Ohlsson C, Carlsten H. Prevalence and risk factors of osteoporosis in female SLE patients-extended report. Rheumatology (Oxford). 2007, 46:1185-90. 10.1093\/rheumatology\/kem105","journal-title":"Rheumatology (Oxford)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer M","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al.. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019, 78:1151-9. 10.1136\/annrheumdis-2018-214819","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer M","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al.. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019, 71:1400-12. 10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg MC","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40:1725. 10.1002\/art.1780400928","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri M","year":"2012","unstructured":"Petri M, Orbai AM, Alarc\u00f3n GS, et al.. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012, 64:2677-86. 10.1002\/art.34473","journal-title":"Arthritis Rheum"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa379","article-title":"Classifying and diagnosing systemic lupus erythematosus in the 21st century","volume":"59","author":"Aringer M","year":"2020","unstructured":"Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology (Oxford). 2020, 59:v4-v11. 10.1093\/rheumatology\/keaa379","journal-title":"Rheumatology (Oxford)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2022.9366","article-title":"Antinuclear antibody-negative systemic lupus erythematosus: how many patients and how to identify?","volume":"37","author":"Li H","year":"2022","unstructured":"Li H, Zheng Y, Chen L, Lin S. Antinuclear antibody-negative systemic lupus erythematosus: how many patients and how to identify?. Arch Rheumatol. 2022, 37:626-34. 10.46497\/ArchRheumatol.2022.9366","journal-title":"Arch Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-020-00449-2","article-title":"Leukoencephalopathy and cerebral edema as the presenting manifestations of SLE in an ANA-negative adolescent female: a case report and review of literature","volume":"18","author":"Theisen A","year":"2020","unstructured":"Theisen A, Bose P, Knight C, Oliver M. Leukoencephalopathy and cerebral edema as the presenting manifestations of SLE in an ANA-negative adolescent female: a case report and review of literature. Pediatr Rheumatol Online J. 2020, 18:58. 10.1186\/s12969-020-00449-2","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1011591","article-title":"SLE classification criteria: science-based icons or algorithmic distractions - an intellectually demanding dilemma","volume":"13","author":"Rekvig OP","year":"2022","unstructured":"Rekvig OP. SLE classification criteria: science-based icons or algorithmic distractions - an intellectually demanding dilemma. Front Immunol. 2022, 13:1011591. 10.3389\/fimmu.2022.1011591","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/416603a","article-title":"Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors","volume":"416","author":"Leadbetter EA","year":"2002","unstructured":"Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002, 416:603-7. 10.1038\/416603a","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23025","article-title":"Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9","volume":"115","author":"Means TK","year":"2005","unstructured":"Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005, 115:407-17. 10.1172\/JCI23025","journal-title":"J Clin Invest"},{"key":"ref27","article-title":"Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis","volume":"5 Suppl 1","author":"Petri M","year":"1996","unstructured":"Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996, 5 Suppl 1:S16-22.","journal-title":"Lupus"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402793","article-title":"Cutting edge: antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase-DNA interaction","volume":"194","author":"An J","year":"2015","unstructured":"An J, Woodward JJ, Sasaki T, Minie M, Elkon KB. Cutting edge: antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase-DNA interaction. J Immunol. 2015, 194:4089-93. 10.4049\/jimmunol.1402793","journal-title":"J Immunol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)","volume":"66","author":"Alarc\u00f3n GS","year":"2007","unstructured":"Alarc\u00f3n GS, McGwin G, Bertoli AM, et al.. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007, 66:1168-72. 10.1136\/ard.2006.068676","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza G","year":"2006","unstructured":"Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al.. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006, 15:577-83. 10.1177\/0961203306071872","journal-title":"Lupus"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","author":"Canadian Hydroxychloroquine Study Group","year":"1991","unstructured":"Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991, 324:150-4. 10.1056\/NEJM199101173240303","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/art.21039","article-title":"Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual","volume":"52","author":"Fessler BJ","year":"2005","unstructured":"Fessler BJ, Alarc\u00f3n GS, McGwin G Jr, et al.. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005, 52:1473-80. 10.1002\/art.21039","journal-title":"Arthritis Rheum"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161351","article-title":"Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus","volume":"44","author":"Fasano S","year":"2017","unstructured":"Fasano S, Pierro L, Pantano I, Iudici M, Valentini G. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol. 2017, 44:1032-8. 10.3899\/jrheum.161351","journal-title":"J Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2313oa","article-title":"Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis","volume":"15","author":"Kasitanon N","year":"2006","unstructured":"Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006, 15:366-70. 10.1191\/0961203306lu2313oa","journal-title":"Lupus"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201089","article-title":"Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study","volume":"71","author":"Hanly JG","year":"2012","unstructured":"Hanly JG, Urowitz MB, Su L, et al.. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis. 2012, 71:1502-9. 10.1136\/annrheumdis-2011-201089","journal-title":"Ann Rheum Dis"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077594","article-title":"Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV)","volume":"67","author":"Andrade RM","year":"2008","unstructured":"Andrade RM, Alarc\u00f3n GS, Gonz\u00e1lez LA, et al.. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis. 2008, 67:829-34. 10.1136\/ard.2007.077594","journal-title":"Ann Rheum Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309104392","article-title":"Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort","volume":"18","author":"Gonz\u00e1lez LA","year":"2009","unstructured":"Gonz\u00e1lez LA, Pons-Estel GJ, Zhang J, Vil\u00e1 LM, Reveille JD, Alarc\u00f3n GS. Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus. 2009, 18:822-30. 10.1177\/0961203309104392","journal-title":"Lupus"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1992.tb14851.x","article-title":"Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine","volume":"127","author":"Ruzicka T","year":"1992","unstructured":"Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992, 127:513-8. 10.1111\/j.1365-2133.1992.tb14851.x","journal-title":"Br J Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.06.018","article-title":"Cutaneous lupus erythematosus: update of therapeutic options part I","volume":"65","author":"Kuhn A","year":"2011","unstructured":"Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol. 2011, 65:e179-93. 10.1016\/j.jaad.2010.06.018","journal-title":"J Am Acad Dermatol"},{"key":"ref40","article-title":"Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus","volume":"21","author":"Williams HJ","year":"1994","unstructured":"Williams HJ, Egger MJ, Singer JZ, et al.. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol. 1994, 21:1457-62.","journal-title":"J Rheumatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3689-2","article-title":"Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial","volume":"58","author":"Wasko MC","year":"2015","unstructured":"Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015, 58:2336-43. 10.1007\/s00125-015-3689-2","journal-title":"Diabetologia"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3109\/03009749609069986","article-title":"Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective","volume":"25","author":"Petri M","year":"1996","unstructured":"Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol. 1996, 25:191-3. 10.3109\/03009749609069986","journal-title":"Scand J Rheumatol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1177\/096120339600500524","article-title":"In vivo models of thrombosis for the antiphospholipid syndrome","volume":"5","author":"Pierangeli SS","year":"1996","unstructured":"Pierangeli SS, Harris EN. In vivo models of thrombosis for the antiphospholipid syndrome. Lupus. 1996, 5:451-5. 10.1177\/096120339600500524","journal-title":"Lupus"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2039oa","article-title":"Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus","volume":"14","author":"Mok CC","year":"2005","unstructured":"Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005, 14:106-12. 10.1191\/0961203305lu2039oa","journal-title":"Lupus"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150671","article-title":"Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials","volume":"43","author":"Herrinton LJ","year":"2016","unstructured":"Herrinton LJ, Liu L, Goldfien R, Michaels MA, Tran TN. Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials. J Rheumatol. 2016, 43:1503-9. 10.3899\/jrheum.150671","journal-title":"J Rheumatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19057","article-title":"Hydroxychloroquine and risk of cancer in patients with primary Sj\u00f6gren syndrome: propensity score matched landmark analysis","volume":"8","author":"Fang YF","year":"2017","unstructured":"Fang YF, Chen YF, Chung TT, et al.. Hydroxychloroquine and risk of cancer in patients with primary Sj\u00f6gren syndrome: propensity score matched landmark analysis. Oncotarget. 2017, 8:80461-71. 10.18632\/oncotarget.19057","journal-title":"Oncotarget"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20133","article-title":"Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus","volume":"62","author":"Wolfe F","year":"2010","unstructured":"Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010, 62:775-84. 10.1002\/acr.20133","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor MF","year":"2011","unstructured":"Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011, 118:415-22. 10.1016\/j.ophtha.2010.11.017","journal-title":"Ophthalmology"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0726-y","article-title":"A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources","volume":"17","author":"Leffler J","year":"2015","unstructured":"Leffler J, Ciacma K, Gullstrand B, Bengtsson AA, Martin M, Blom AM. A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources. Arthritis Res Ther. 2015, 17:205. 10.1186\/s13075-015-0726-y","journal-title":"Arthritis Res Ther"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis A","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, et al.. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019, 78:736-45. 10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier E","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020, 16:155-66. 10.1038\/s41584-020-0372-x","journal-title":"Nat Rev Rheumatol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce IN","year":"2015","unstructured":"Bruce IN, O'Keeffe AG, Farewell V, et al.. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015, 74:1706-13. 10.1136\/annrheumdis-2013-205171","journal-title":"Ann Rheum Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160214","article-title":"Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study","volume":"45","author":"Chen HL","year":"2018","unstructured":"Chen HL, Shen LJ, Hsu PN, Shen CY, Hall SA, Hsiao FY. Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. J Rheumatol. 2018, 45:83-9. 10.3899\/jrheum.160214","journal-title":"J Rheumatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23199","article-title":"From childhood to adulthood: the trajectory of damage in patients with juvenile-onset systemic lupus erythematosus","volume":"69","author":"Lim LS","year":"2017","unstructured":"Lim LS, Pullenayegum E, Lim L, Gladman D, Feldman B, Silverman E. From childhood to adulthood: the trajectory of damage in patients with juvenile-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017, 69:1627-35. 10.1002\/acr.23199","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu412","article-title":"Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years","volume":"54","author":"Yee CS","year":"2015","unstructured":"Yee CS, Su L, Toescu V, et al.. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford). 2015, 54:836-43. 10.1093\/rheumatology\/keu412","journal-title":"Rheumatology (Oxford)"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew377","article-title":"Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus","volume":"56","author":"Tsang-A-Sjoe MW","year":"2017","unstructured":"Tsang-A-Sjoe MW, Bultink IE, Heslinga M, Voskuyl AE. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford). 2017, 56:121-8. 10.1093\/rheumatology\/kew377","journal-title":"Rheumatology (Oxford)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080828","article-title":"Prednisone, lupus activity, and permanent organ damage","volume":"36","author":"Thamer M","year":"2009","unstructured":"Thamer M, Hern\u00e1n MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009, 36:560-4. 10.3899\/jrheum.080828","journal-title":"J Rheumatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.05.011","article-title":"Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis","volume":"14","author":"Ruiz-Arruza I","year":"2015","unstructured":"Ruiz-Arruza I, Barbosa C, Ugarte A, Ruiz-Irastorza G. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev. 2015, 14:875-9. 10.1016\/j.autrev.2015.05.011","journal-title":"Autoimmun Rev"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000066","article-title":"Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort","volume":"2","author":"Al Sawah S","year":"2015","unstructured":"Al Sawah S, Zhang X, Zhu B, Magder LS, Foster SA, Iikuni N, Petri M. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med. 2015, 2:e000066. 10.1136\/lupus-2014-000066","journal-title":"Lupus Sci Med"},{"key":"ref60","article-title":"Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone","volume":"33","author":"Danowski A","year":"2006","unstructured":"Danowski A, Magder L, Petri M. Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. J Rheumatol. 2006, 33:57-60.","journal-title":"J Rheumatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0673-8","article-title":"Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis","volume":"14","author":"Singh JA","year":"2016","unstructured":"Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016, 14:137. 10.1186\/s12916-016-0673-8","journal-title":"BMC Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59010056","article-title":"Synthetic pharmacotherapy for systemic lupus erythematosus: potential mechanisms of action, efficacy, and safety","volume":"59","author":"T\u00e9llez Ar\u00e9valo AM","year":"2022","unstructured":"T\u00e9llez Ar\u00e9valo AM, Quaye A, Rojas-Rodr\u00edguez LC, Poole BD, Baracaldo-Santamar\u00eda D, Tellez Freitas CM. Synthetic pharmacotherapy for systemic lupus erythematosus: potential mechanisms of action, efficacy, and safety. Medicina (Kaunas). 2022, 59:10.3390\/medicina59010056","journal-title":"Medicina (Kaunas)"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers","volume":"12","author":"Brown PM","year":"2016","unstructured":"Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016, 12:731-42. 10.1038\/nrrheum.2016.175","journal-title":"Nat Rev Rheumatol"},{"key":"ref64","article-title":"Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus","volume":"26","author":"Carneiro JR","year":"1999","unstructured":"Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999, 26:1275-9.","journal-title":"J Rheumatol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1002\/art.24068","article-title":"Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"59","author":"Fortin PR","year":"2008","unstructured":"Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008, 59:1796-804. 10.1002\/art.24068","journal-title":"Arthritis Rheum"},{"key":"ref66","article-title":"Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis","volume":"25","author":"Rahman P","year":"1998","unstructured":"Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol. 1998, 25:243-6.","journal-title":"J Rheumatol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.06.017","article-title":"Cutaneous lupus erythematosus: update of therapeutic options part II","volume":"65","author":"Kuhn A","year":"2011","unstructured":"Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol. 2011, 65:e195-213. 10.1016\/j.jaad.2010.06.017","journal-title":"J Am Acad Dermatol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801917-7.00062-0","article-title":"Chapter 62 - cytotoxic-immunosuppressive drug treatment","author":"Frangou EA","year":"2016","unstructured":"Frangou EA, Bertsias G, Boumpas DT. Chapter 62 - cytotoxic-immunosuppressive drug treatment. Systemic lupus erythematosus: basic, applied and clinical aspects. Tsokos GC (ed): Academic Press, 2016. 533-41. 10.1016\/B978-0-12-801917-7.00062-0"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000139","article-title":"Characteristics related to early secondary amenorrhoea and pregnancy among women diagnosed with systemic lupus erythematosus: an analysis using the GOAL study","volume":"3","author":"Knight JH","year":"2016","unstructured":"Knight JH, Howards PP, Spencer JB, Tsagaris KC, Lim SS. Characteristics related to early secondary amenorrhoea and pregnancy among women diagnosed with systemic lupus erythematosus: an analysis using the GOAL study. Lupus Sci Med. 2016, 3:e000139. 10.1136\/lupus-2015-000139","journal-title":"Lupus Sci Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/art.40079","article-title":"Brief report: the Euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-M\u00fcllerian hormone","volume":"69","author":"Tamirou F","year":"2017","unstructured":"Tamirou F, Husson SN, Gruson D, Debi\u00e8ve F, Lauwerys BR, Houssiau FA. Brief report: the Euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-M\u00fcllerian hormone. Arthritis Rheumatol. 2017, 69:1267-71. 10.1002\/art.40079","journal-title":"Arthritis Rheumatol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/art.37719","article-title":"Anti-m\u00fcllerian hormone and ovarian reserve in systemic lupus erythematosus","volume":"65","author":"Mok CC","year":"2013","unstructured":"Mok CC, Chan PT, To CH. Anti-m\u00fcllerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum. 2013, 65:206-10. 10.1002\/art.37719","journal-title":"Arthritis Rheum"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli L","year":"2017","unstructured":"Andreoli L, Bertsias GK, Agmon-Levin N, et al.. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome. Ann Rheum Dis. 2017, 76:476-85. 10.1136\/annrheumdis-2016-209770","journal-title":"Ann Rheum Dis"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.05.008","article-title":"Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases","volume":"41","author":"Blumenfeld Z","year":"2011","unstructured":"Blumenfeld Z, Mischari O, Schultz N, Boulman N, Balbir-Gurman A. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. Semin Arthritis Rheum. 2011, 41:346-52. 10.1016\/j.semarthrit.2011.05.008","journal-title":"Semin Arthritis Rheum"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2011.650752","article-title":"Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients","volume":"28","author":"Marder W","year":"2012","unstructured":"Marder W, McCune WJ, Wang L, et al.. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012, 28:624-7. 10.3109\/09513590.2011.650752","journal-title":"Gynecol Endocrinol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202099","article-title":"Lymphoma risk in systemic lupus: effects of disease activity versus treatment","volume":"73","author":"Bernatsky S","year":"2014","unstructured":"Bernatsky S, Ramsey-Goldman R, Joseph L, et al.. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014, 73:138-42. 10.1136\/annrheumdis-2012-202099","journal-title":"Ann Rheum Dis"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew457","article-title":"Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study","volume":"56","author":"Hsu CY","year":"2017","unstructured":"Hsu CY, Lin MS, Su YJ, et al.. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 2017, 56:620-8. 10.1093\/rheumatology\/kew457","journal-title":"Rheumatology (Oxford)"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.12.1087","article-title":"Current and novel therapeutics in the treatment of systemic lupus erythematosus","volume":"127","author":"Yildirim-Toruner C","year":"2011","unstructured":"Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011, 127:303-12; quiz 313-4. 10.1016\/j.jaci.2010.12.1087","journal-title":"J Allergy Clin Immunol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780180106","article-title":"Long-term maintenance therapy with azathioprine in systemic lupus erythematosus","volume":"18","author":"Ginzler E","year":"1975","unstructured":"Ginzler E, Sharon E, Diamond H, Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 1975, 18:27-34. 10.1002\/art.1780180106","journal-title":"Arthritis Rheum"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780140511","article-title":"Azathioprine in the treatment of systemic lupus erythematosus. A controlled study","volume":"14","author":"Sztejnbok M","year":"1971","unstructured":"Sztejnbok M, Stewart A, Diamond H, Kaplan D. Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum. 1971, 14:639-45. 10.1002\/art.1780140511","journal-title":"Arthritis Rheum"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep396","article-title":"The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE","volume":"49","author":"Griffiths B","year":"2010","unstructured":"Griffiths B, Emery P, Ryan V, et al.. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford). 2010, 49:723-32. 10.1093\/rheumatology\/kep396","journal-title":"Rheumatology (Oxford)"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00538.x","article-title":"Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites","volume":"101","author":"de Boer NK","year":"2006","unstructured":"de Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol. 2006, 101:1390-2. 10.1111\/j.1572-0241.2006.00538.x","journal-title":"Am J Gastroenterol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen JC","year":"2020","unstructured":"Broen JC, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol. 2020, 16:167-78. 10.1038\/s41584-020-0374-8","journal-title":"Nat Rev Rheumatol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1080\/03009740701607042","article-title":"Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review","volume":"36","author":"Mok CC","year":"2007","unstructured":"Mok CC. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol. 2007, 36:329-37. 10.1080\/03009740701607042","journal-title":"Scand J Rheumatol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150779","article-title":"Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study","volume":"43","author":"Tselios K","year":"2016","unstructured":"Tselios K, Gladman DD, Su J, Urowitz MB. Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. J Rheumatol. 2016, 43:552-8. 10.3899\/jrheum.150779","journal-title":"J Rheumatol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100130","article-title":"Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis","volume":"38","author":"Touma Z","year":"2011","unstructured":"Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011, 38:69-78. 10.3899\/jrheum.100130","journal-title":"J Rheumatol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial","volume":"76","author":"Ordi-Ros J","year":"2017","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M, et al.. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017, 76:1575-82. 10.1136\/annrheumdis-2016-210882","journal-title":"Ann Rheum Dis"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00259.x","article-title":"FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3","volume":"61","author":"Ikezumi Y","year":"2002","unstructured":"Ikezumi Y, Kanno K, Koike H, Tomita M, Uchiyama M, Shimizu F, Kawachi H. FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3. Kidney Int. 2002, 61:1339-50. 10.1046\/j.1523-1755.2002.00259.x","journal-title":"Kidney Int"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132724","article-title":"Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis","volume":"10","author":"Liao R","year":"2015","unstructured":"Liao R, Liu Q, Zheng Z, et al.. Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLoS One. 2015, 10:e0132724. 10.1371\/journal.pone.0132724","journal-title":"PLoS One"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul C","year":"2008","unstructured":"Faul C, Donnelly M, Merscher-Gomez S, et al.. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008, 14:931-8. 10.1038\/nm.1857","journal-title":"Nat Med"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu Z","year":"2015","unstructured":"Liu Z, Zhang H, Liu Z, et al.. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015, 162:18-26. 10.7326\/M14-1030","journal-title":"Ann Intern Med"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312448105","article-title":"Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study","volume":"21","author":"Wang S","year":"2012","unstructured":"Wang S, Li X, Qu L, et al.. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus. 2012, 21:1025-35. 10.1177\/0961203312448105","journal-title":"Lupus"},{"key":"ref92","article-title":"Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study","volume":"31","author":"Fei Y","year":"2013","unstructured":"Fei Y, Wu Q, Zhang W, et al.. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp Rheumatol. 2013, 31:62-8.","journal-title":"Clin Exp Rheumatol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up","volume":"75","author":"Mok CC","year":"2016","unstructured":"Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016, 75:30-6. 10.1136\/annrheumdis-2014-206456","journal-title":"Ann Rheum Dis"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: a systematic review and meta-analysis","volume":"15","author":"Hannah J","year":"2016","unstructured":"Hannah J, Casian A, D'Cruz D. Tacrolimus use in lupus nephritis: a systematic review and meta-analysis. Autoimmun Rev. 2016, 15:93-101. 10.1016\/j.autrev.2015.09.006","journal-title":"Autoimmun Rev"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2017.05.006","article-title":"Lupus nephritis and pregnancy: concerns and management","volume":"37","author":"Lightstone L","year":"2017","unstructured":"Lightstone L, Hladunewich MA. Lupus nephritis and pregnancy: concerns and management. Semin Nephrol. 2017, 37:347-53. 10.1016\/j.semnephrol.2017.05.006","journal-title":"Semin Nephrol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults","volume":"393","author":"Durcan L","year":"2019","unstructured":"Durcan L, O\u2019Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019, 393:2332-43. 10.1016\/S0140-6736(19)30237-5","journal-title":"Lancet"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie R","year":"2011","unstructured":"Furie R, Petri M, Zamani O, et al.. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011, 63:3918-30. 10.1002\/art.30613","journal-title":"Arthritis Rheum"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra SV","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, et al.. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011, 377:721-31. 10.1016\/S0140-6736(10)61354-2","journal-title":"Lancet"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.09.004","article-title":"Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study","volume":"86","author":"Iaccarino L","year":"2018","unstructured":"Iaccarino L, Andreoli L, Bocci EB, et al.. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018, 86:1-8. 10.1016\/j.jaut.2017.09.004","journal-title":"J Autoimmun"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi S","year":"2012","unstructured":"Manzi S, S\u00e1nchez-Guerrero J, Merrill JT, et al.. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012, 71:1833-8. 10.1136\/annrheumdis-2011-200831","journal-title":"Ann Rheum Dis"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven RF","year":"2012","unstructured":"van Vollenhoven RF, Petri MA, Cervera R, et al.. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012, 71:1343-9. 10.1136\/annrheumdis-2011-200937","journal-title":"Ann Rheum Dis"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"D\u00edaz-Lagares C","year":"2012","unstructured":"D\u00edaz-Lagares C, Croca S, Sangle S, et al.. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012, 11:357-64. 10.1016\/j.autrev.2011.10.009","journal-title":"Autoimmun Rev"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313509295","article-title":"Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis","volume":"22","author":"Duxbury B","year":"2013","unstructured":"Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus. 2013, 22:1489-503. 10.1177\/0961203313509295","journal-title":"Lupus"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases","volume":"18","author":"Ramos-Casals M","year":"2009","unstructured":"Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009, 18:767-76. 10.1177\/0961203309106174","journal-title":"Lupus"},{"key":"ref105","article-title":"Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry","volume":"33","author":"Iaccarino L","year":"2015","unstructured":"Iaccarino L, Bartoloni E, Carli L, et al.. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol. 2015, 33:449-56.","journal-title":"Clin Exp Rheumatol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315578764","article-title":"Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus","volume":"24","author":"Olfat M","year":"2015","unstructured":"Olfat M, Silverman ED, Levy DM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus. 2015, 24:966-72. 10.1177\/0961203315578764","journal-title":"Lupus"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry","volume":"62","author":"Terrier B","year":"2010","unstructured":"Terrier B, Amoura Z, Ravaud P, et al.. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010, 62:2458-66. 10.1002\/art.27541","journal-title":"Arthritis Rheum"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh S","year":"2015","unstructured":"Chugh S, Darvish-Kazem S, Lim W, et al.. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015, 2:e75-81. 10.1016\/S2352-3026(15)00003-4","journal-title":"Lancet Haematol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp002","article-title":"Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study","volume":"24","author":"Boletis JN","year":"2009","unstructured":"Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant. 2009, 24:2157-60. 10.1093\/ndt\/gfp002","journal-title":"Nephrol Dial Transplant"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60889-2","article-title":"Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment","volume":"382","author":"Murphy G","year":"2013","unstructured":"Murphy G, Lisnevskaia L, Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet. 2013, 382:809-18. 10.1016\/S0140-6736(13)60889-2","journal-title":"Lancet"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis A","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021, 80:14-25. 10.1136\/annrheumdis-2020-218272","journal-title":"Ann Rheum Dis"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian J","year":"2023","unstructured":"Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023, 82:351-6. 10.1136\/ard-2022-223035","journal-title":"Ann Rheum Dis"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000480","article-title":"Epidemiology of systemic lupus erythematosus: an update","volume":"30","author":"Stojan G","year":"2018","unstructured":"Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018, 30:144-50. 10.1097\/BOR.0000000000000480","journal-title":"Curr Opin Rheumatol"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1002\/art.22641","article-title":"Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data","volume":"56","author":"Chakravarty EF","year":"2007","unstructured":"Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum. 2007, 56:2092-4. 10.1002\/art.22641","journal-title":"Arthritis Rheum"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199909000-00005","article-title":"The role of sex hormones in systemic lupus erythematosus","volume":"11","author":"Lahita RG","year":"1999","unstructured":"Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol. 1999, 11:352-6. 10.1097\/00002281-199909000-00005","journal-title":"Curr Opin Rheumatol"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12249","article-title":"Evaluation of ovarian reserve tests in women with systemic lupus erythematosus","volume":"72","author":"Ulug P","year":"2014","unstructured":"Ulug P, Oner G, Kasap B, Akbas EM, Ozcicek F. Evaluation of ovarian reserve tests in women with systemic lupus erythematosus. Am J Reprod Immunol. 2014, 72:85-8. 10.1111\/aji.12249","journal-title":"Am J Reprod Immunol"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1191\/0961203302lu163oa","article-title":"Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations","volume":"11","author":"Pasoto SG","year":"2002","unstructured":"Pasoto SG, Mendon\u00e7a BB, Bonf\u00e1 E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus. 2002, 11:175-80. 10.1191\/0961203302lu163oa","journal-title":"Lupus"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312449492","article-title":"Protein-losing enteropathy and premature ovarian failure in a young woman with systemic lupus erythematosus","volume":"21","author":"Chang YS","year":"2012","unstructured":"Chang YS, Lai CC, Chen WS, Wang SH, Chou CT, Tsai CY. Protein-losing enteropathy and premature ovarian failure in a young woman with systemic lupus erythematosus. Lupus. 2012, 21:1237-9. 10.1177\/0961203312449492","journal-title":"Lupus"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2016.07.001","article-title":"Reproductive aspects of systemic lupus erythematosus","volume":"117","author":"Oktem O","year":"2016","unstructured":"Oktem O, Yagmur H, Bengisu H, Urman B. Reproductive aspects of systemic lupus erythematosus. J Reprod Immunol. 2016, 117:57-65. 10.1016\/j.jri.2016.07.001","journal-title":"J Reprod Immunol"},{"key":"ref120","article-title":"Premature ovarian failure in patients affected by systemic lupus erythematosus: a cross-sectional study","volume":"38","author":"Ceccarelli F","year":"2020","unstructured":"Ceccarelli F, Orefice V, Perrone G, et al.. Premature ovarian failure in patients affected by systemic lupus erythematosus: a cross-sectional study. Clin Exp Rheumatol. 2020, 38:450-54.","journal-title":"Clin Exp Rheumatol"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2020.10.002","article-title":"Pregnancy and management in women with rheumatoid arthritis, systemic lupus erythematosus, and obstetric antiphospholipid syndrome","volume":"105","author":"Castro-Gutierrez A","year":"2021","unstructured":"Castro-Gutierrez A, Young K, Bermas BL. Pregnancy and management in women with rheumatoid arthritis, systemic lupus erythematosus, and obstetric antiphospholipid syndrome. Med Clin North Am. 2021, 105:341-53. 10.1016\/j.mcna.2020.10.002","journal-title":"Med Clin North Am"},{"key":"ref122","unstructured":"A better family plan. (2007). Accessed. May 3, 2023: https:\/\/www.the-rheumatologist.org\/article\/a-better-family-plan\/5\/."},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1002\/art.23712","article-title":"Risk of unintended pregnancy among women with systemic lupus erythematosus","volume":"59","author":"Schwarz EB","year":"2008","unstructured":"Schwarz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum. 2008, 59:863-6. 10.1002\/art.23712","journal-title":"Arthritis Rheum"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20402","article-title":"Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?","volume":"63","author":"Yazdany J","year":"2011","unstructured":"Yazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis JZ, Chakravarty E, Schwarz EB. Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?. Arthritis Care Res (Hoboken). 2011, 63:358-65. 10.1002\/acr.20402","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref125","unstructured":"Summary of recommendations for contraceptives in SLE\/APS patients. (2023). Accessed. April 28, 2023: https:\/\/www.uptodate.com\/contents\/image?csi=d04efd99-2dff-473e-8fcb-adde5945abc3&amp;source=contentShare&amp;imageKey=RHEUM%2...."},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050817","article-title":"A trial of contraceptive methods in women with systemic lupus erythematosus","volume":"353","author":"S\u00e1nchez-Guerrero J","year":"2005","unstructured":"S\u00e1nchez-Guerrero J, Uribe AG, Jim\u00e9nez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, Cravioto MD. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005, 353:2539-49. 10.1056\/NEJMoa050817","journal-title":"N Engl J Med"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1177\/0961203306071706","article-title":"Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil)","volume":"15","author":"Pisoni CN","year":"2006","unstructured":"Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus. 2006, 15:877-80. 10.1177\/0961203306071706","journal-title":"Lupus"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.03.031","article-title":"A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus","volume":"197","author":"Stringer EM","year":"2007","unstructured":"Stringer EM, Kaseba C, Levy J, et al.. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007, 197:144.e1-8. 10.1016\/j.ajog.2007.03.031","journal-title":"Am J Obstet Gynecol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6503a1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2016","volume":"65","author":"Curtis KM","year":"2016","unstructured":"Curtis KM, Tepper NK, Jatlaoui TC, et al.. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016, 65:1-103. 10.15585\/mmwr.rr6503a1","journal-title":"MMWR Recomm Rep"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4944","article-title":"Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis","volume":"345","author":"Mantha S","year":"2012","unstructured":"Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012, 345:e4944. 10.1136\/bmj.e4944","journal-title":"BMJ"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri M","year":"2005","unstructured":"Petri M, Kim MY, Kalunian KC, et al.. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005, 353:2550-8. 10.1056\/NEJMoa051135","journal-title":"N Engl J Med"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the ratio study: a case-control study","volume":"8","author":"Urbanus RT","year":"2009","unstructured":"Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the ratio study: a case-control study. Lancet Neurol. 2009, 8:998-1005. 10.1016\/S1474-4422(09)70239-X","journal-title":"Lancet Neurol"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2005.03.005","article-title":"Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive","volume":"72","author":"van den Heuvel MW","year":"2005","unstructured":"van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005, 72:168-74. 10.1016\/j.contraception.2005.03.005","journal-title":"Contraception"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2014.5077","article-title":"Prevalence of low bone mass and osteoporosis in long-term users of the injectable contraceptive depot medroxyprogesterone acetate","volume":"24","author":"Modesto W","year":"2015","unstructured":"Modesto W, Bahamondes MV, Bahamondes L. Prevalence of low bone mass and osteoporosis in long-term users of the injectable contraceptive depot medroxyprogesterone acetate. J Womens Health (Larchmt). 2015, 24:636-40. 10.1089\/jwh.2014.5077","journal-title":"J Womens Health (Larchmt)"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310397967","article-title":"Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus","volume":"20","author":"Kwok LW","year":"2011","unstructured":"Kwok LW, Tam LS, Zhu T, Leung YY, Li E. Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus. 2011, 20:829-36. 10.1177\/0961203310397967","journal-title":"Lupus"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2005.02.063","article-title":"Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus","volume":"192","author":"Chakravarty EF","year":"2005","unstructured":"Chakravarty EF, Col\u00f3n I, Langen ES, Nix DA, El-Sayed YY, Genovese MC, Druzin ML. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol. 2005, 192:1897-904. 10.1016\/j.ajog.2005.02.063","journal-title":"Am J Obstet Gynecol"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1002\/art.21663","article-title":"Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis","volume":"54","author":"Chakravarty EF","year":"2006","unstructured":"Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006, 54:899-907. 10.1002\/art.21663","journal-title":"Arthritis Rheum"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2008.03.012","article-title":"A national study of the complications of lupus in pregnancy","volume":"199","author":"Clowse ME","year":"2008","unstructured":"Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008, 199:127.e1-6. 10.1016\/j.ajog.2008.03.012","journal-title":"Am J Obstet Gynecol"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.01.014","article-title":"Maternal and perinatal outcomes of pregnancies in systemic lupus erythematosus: a nationwide population-based study","volume":"50","author":"Chen YJ","year":"2020","unstructured":"Chen YJ, Chang JC, Lai EL, et al.. Maternal and perinatal outcomes of pregnancies in systemic lupus erythematosus: a nationwide population-based study. Semin Arthritis Rheum. 2020, 50:451-7. 10.1016\/j.semarthrit.2020.01.014","journal-title":"Semin Arthritis Rheum"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211641","article-title":"Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study","volume":"77","author":"Skorpen CG","year":"2018","unstructured":"Skorpen CG, Lydersen S, Gilboe IM, et al.. Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study. Ann Rheum Dis. 2018, 77:264-9. 10.1136\/annrheumdis-2017-211641","journal-title":"Ann Rheum Dis"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1002\/art.20864","article-title":"The impact of increased lupus activity on obstetric outcomes","volume":"52","author":"Clowse ME","year":"2005","unstructured":"Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005, 52:514-21. 10.1002\/art.20864","journal-title":"Arthritis Rheum"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-1941-4","article-title":"Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy","volume":"31","author":"Saavedra MA","year":"2012","unstructured":"Saavedra MA, Cruz-Reyes C, Vera-Lastra O, Romero GT, Cruz-Cruz P, Arias-Flores R, Jara LJ. Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy. Clin Rheumatol. 2012, 31:813-9. 10.1007\/s10067-012-1941-4","journal-title":"Clin Rheumatol"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308097575","article-title":"Maternal and foetal outcomes in pregnant patients with active lupus nephritis","volume":"18","author":"Wagner SJ","year":"2009","unstructured":"Wagner SJ, Craici I, Reed D, et al.. Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus. 2009, 18:342-7. 10.1177\/0961203308097575","journal-title":"Lupus"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/2ju0yv","article-title":"Anti-SSA\/Ro positivity and congenital heart block: obstetric and foetal outcome in a cohort of anti-SSA\/Ro positive pregnant patients with and without autoimmune diseases","volume":"41","author":"Fredi M","year":"2023","unstructured":"Fredi M, Argolini LM, Angeli F, et al.. Anti-SSA\/Ro positivity and congenital heart block: obstetric and foetal outcome in a cohort of anti-SSA\/Ro positive pregnant patients with and without autoimmune diseases. Clin Exp Rheumatol. 2023, 41:685-93. 10.55563\/clinexprheumatol\/2ju0yv","journal-title":"Clin Exp Rheumatol"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2022.122601","article-title":"Neonatal lupus erythematosus - prevention is better than cure","volume":"39","author":"Liszewska A","year":"2022","unstructured":"Liszewska A, Wo\u017aniacka A. Neonatal lupus erythematosus - prevention is better than cure. Postepy Dermatol Alergol. 2022, 39:1021-6. 10.5114\/ada.2022.122601","journal-title":"Postepy Dermatol Alergol"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1002\/art.39668","article-title":"Brief report: changes in antiphospholipid antibody titers during pregnancy: effects on pregnancy outcomes","volume":"68","author":"Yelnik CM","year":"2016","unstructured":"Yelnik CM, Porter TF, Branch DW, et al.. Brief report: changes in antiphospholipid antibody titers during pregnancy: effects on pregnancy outcomes. Arthritis Rheumatol. 2016, 68:1964-9. 10.1002\/art.39668","journal-title":"Arthritis Rheumatol"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.7.486","article-title":"Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases","volume":"55","author":"Buchanan NM","year":"1996","unstructured":"Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis. 1996, 55:486-8. 10.1136\/ard.55.7.486","journal-title":"Ann Rheum Dis"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212535","article-title":"Effect of pregnancy on disease flares in patients with systemic lupus erythematosus","volume":"77","author":"Eudy AM","year":"2018","unstructured":"Eudy AM, Siega-Riz AM, Engel SM, Franceschini N, Howard AG, Clowse ME, Petri M. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis. 2018, 77:855-60. 10.1136\/annrheumdis-2017-212535","journal-title":"Ann Rheum Dis"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13830","article-title":"Use of antimalarial drugs is associated with a lower risk of preeclampsia in lupus pregnancy: a prospective cohort study","volume":"23","author":"Saavedra M\u00c1","year":"2020","unstructured":"Saavedra M\u00c1, Miranda-Hern\u00e1ndez D, Lara-Mej\u00eda A, et al.. Use of antimalarial drugs is associated with a lower risk of preeclampsia in lupus pregnancy: a prospective cohort study. Int J Rheum Dis. 2020, 23:633-40. 10.1111\/1756-185X.13830","journal-title":"Int J Rheum Dis"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S282604","article-title":"Systemic lupus erythematosus management in pregnancy","volume":"14","author":"Dao KH","year":"2022","unstructured":"Dao KH, Bermas BL. Systemic lupus erythematosus management in pregnancy. Int J Womens Health. 2022, 14:199-211. 10.2147\/IJWH.S282604","journal-title":"Int J Womens Health"},{"key":"ref151","article-title":"Hydroxychloroquine in pregnant patients with systemic lupus erythematosus","volume":"23","author":"Parke A","year":"1996","unstructured":"Parke A, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol. 1996, 23:1715-8.","journal-title":"J Rheumatol"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1191\/096120301678646137","article-title":"Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study","volume":"10","author":"Levy RA","year":"2001","unstructured":"Levy RA, Vilela VS, Cataldo MJ, et al.. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001, 10:401-4. 10.1191\/096120301678646137","journal-title":"Lupus"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132952","article-title":"Maternal systemic lupus erythematosus (SLE) high risk for preterm delivery and not for long-term neurological morbidity of the offspring","volume":"10","author":"Davidov D","year":"2021","unstructured":"Davidov D, Sheiner E, Wainstock T, Miodownik S, Pariente G. Maternal systemic lupus erythematosus (SLE) high risk for preterm delivery and not for long-term neurological morbidity of the offspring. J Clin Med. 2021, 10:10.3390\/jcm10132952","journal-title":"J Clin Med"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.14781","article-title":"Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force recommendation statement","volume":"326","author":"Davidson KW","year":"2021","unstructured":"Davidson KW, Barry MJ, Mangione CM, et al.. Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force recommendation statement. JAMA. 2021, 326:1186-91. 10.1001\/jama.2021.14781","journal-title":"JAMA"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.101063","article-title":"Corticosteroid use during pregnancy and risk of orofacial clefts","volume":"183","author":"Hviid A","year":"2011","unstructured":"Hviid A, M\u00f8lgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011, 183:796-804. 10.1503\/cmaj.101063","journal-title":"CMAJ"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000055","article-title":"Rheumatoid arthritis medications and lactation","volume":"26","author":"Sammaritano LR","year":"2014","unstructured":"Sammaritano LR, Bermas BL. Rheumatoid arthritis medications and lactation. Curr Opin Rheumatol. 2014, 26:354-60. 10.1097\/BOR.0000000000000055","journal-title":"Curr Opin Rheumatol"},{"key":"ref157","unstructured":"Nonsteroidal anti-inflammatory drugs (NSAIDs). drug safety communication - avoid use of NSAIDs in pregnancy at 20 weeks or later. (2020). Accessed: May 1, 2023: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/nonsteroidal-anti-inflammatory-drugs-nsaids-drug-safety...."},{"key":"ref158","unstructured":"FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. (2022). Accessed. May 1, 2023: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-bec...."},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e31828a4b54","article-title":"Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation","volume":"116","author":"Bloor M","year":"2013","unstructured":"Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013, 116:1063-75. 10.1213\/ANE.0b013e31828a4b54","journal-title":"Anesth Analg"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2987-x","article-title":"Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome","volume":"34","author":"Saavedra M\u00c1","year":"2015","unstructured":"Saavedra M\u00c1, S\u00e1nchez A, Morales S, \u00c1ngeles U, Jara LJ. Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. Clin Rheumatol. 2015, 34:1211-6. 10.1007\/s10067-015-2987-x","journal-title":"Clin Rheumatol"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318770536","article-title":"The efficacy of adjunct tacrolimus treatment in pregnancy outcomes in patients with systemic lupus erythematosus","volume":"27","author":"Ichinose K","year":"2018","unstructured":"Ichinose K, Sato S, Kitajima Y, et al.. The efficacy of adjunct tacrolimus treatment in pregnancy outcomes in patients with systemic lupus erythematosus. Lupus. 2018, 27:1312-20. 10.1177\/0961203318770536","journal-title":"Lupus"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221148334","article-title":"Safety of tacrolimus use during pregnancy and related pregnancy outcomes in patients with systemic lupus erythematosus: a retrospective single-center analysis in Japan","volume":"32","author":"Kitada A","year":"2023","unstructured":"Kitada A, Nakai T, Fukui S, et al.. Safety of tacrolimus use during pregnancy and related pregnancy outcomes in patients with systemic lupus erythematosus: a retrospective single-center analysis in Japan. Lupus. 2023, 32:352-62. 10.1177\/09612033221148334","journal-title":"Lupus"},{"key":"ref163","article-title":"Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy","volume":"40","author":"Hussein MM","year":"1993","unstructured":"Hussein MM, Mooij JM, Roujouleh H. Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol. 1993, 40:160-3.","journal-title":"Clin Nephrol"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.06.005","article-title":"Pregnancy outcomes in patients treated with belimumab: report from real-world experience","volume":"51","author":"Kao JH","year":"2021","unstructured":"Kao JH, Lan TY, Lu CH, Cheng CF, Huang YM, Shen CY, Hsieh SC. Pregnancy outcomes in patients treated with belimumab: report from real-world experience. Semin Arthritis Rheum. 2021, 51:963-8. 10.1016\/j.semarthrit.2021.06.005","journal-title":"Semin Arthritis Rheum"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221141805","article-title":"Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab","volume":"32","author":"Lai Y","year":"2023","unstructured":"Lai Y, Li B, Huang J, et al.. Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab. Lupus. 2023, 32:149-54. 10.1177\/09612033221141805","journal-title":"Lupus"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221143286","article-title":"Dilemma of belimumab therapy (dis)continuation during pregnancy: results of a retrospective study in eudravigilance","volume":"32","author":"Ghalandari N","year":"2023","unstructured":"Ghalandari N, Crijns HJ, Dolhain RJ, Hazes JM, van Puijenbroek EP. Dilemma of belimumab therapy (dis)continuation during pregnancy: results of a retrospective study in eudravigilance. Lupus. 2023, 32:189-97. 10.1177\/09612033221143286","journal-title":"Lupus"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen C","year":"2016","unstructured":"G\u00f6testam Skorpen C, Hoeltzenbein M, Tincani A, et al.. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016, 75:795-810. 10.1136\/annrheumdis-2015-208840","journal-title":"Ann Rheum Dis"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev404","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids","volume":"55","author":"Flint J","year":"2016","unstructured":"Flint J, Panchal S, Hurrell A, et al.. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016, 55:1693-7. 10.1093\/rheumatology\/kev404","journal-title":"Rheumatology (Oxford)"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev405","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part II: analgesics and other drugs used in rheumatology practice","volume":"55","author":"Flint J","year":"2016","unstructured":"Flint J, Panchal S, Hurrell A, et al.. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part II: analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford). 2016, 55:1698-702. 10.1093\/rheumatology\/kev405","journal-title":"Rheumatology (Oxford)"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2013.03.004","article-title":"How safe are anti-rheumatic drugs during pregnancy?","volume":"13","author":"\u00d8stensen M","year":"2013","unstructured":"\u00d8stensen M, F\u00f6rger F. How safe are anti-rheumatic drugs during pregnancy?. Curr Opin Pharmacol. 2013, 13:470-5. 10.1016\/j.coph.2013.03.004","journal-title":"Curr Opin Pharmacol"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.1002\/tcm.1770050202","article-title":"Cyclophosphamide teratogenesis: a review","volume":"5","author":"Mirkes PE","year":"1985","unstructured":"Mirkes PE. Cyclophosphamide teratogenesis: a review. Teratog Carcinog Mutagen. 1985, 5:75-88. 10.1002\/tcm.1770050202","journal-title":"Teratog Carcinog Mutagen"},{"key":"ref172","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5017","article-title":"Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: a retrospective cohort study","volume":"29","author":"Thai TN","year":"2020","unstructured":"Thai TN, Sarayani A, Wang X, Albogami Y, Rasmussen SA, Winterstein AG. Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2020, 29:716-24. 10.1002\/pds.5017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref173","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.3.219","article-title":"The safety of mycophenolate mofetil in pregnancy","volume":"7","author":"Pisoni CN","year":"2008","unstructured":"Pisoni CN, D'Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf. 2008, 7:219-22. 10.1517\/14740338.7.3.219","journal-title":"Expert Opin Drug Saf"},{"key":"ref174","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.03.088","article-title":"A case of coloboma in a newborn to a woman taking mycophenolate mofetil in pregnancy after kidney transplantation","volume":"41","author":"Dei Malatesta MF","year":"2009","unstructured":"Dei Malatesta MF, Rocca B, Gentile T, et al.. A case of coloboma in a newborn to a woman taking mycophenolate mofetil in pregnancy after kidney transplantation. Transplant Proc. 2009, 41:1407-9. 10.1016\/j.transproceed.2009.03.088","journal-title":"Transplant Proc"},{"key":"ref175","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.908433","article-title":"Congenital esophageal atresia and microtia in a newborn secondary to mycophenolate mofetil exposure during pregnancy: a case report and review of the literature","volume":"19","author":"Alsebayel MM","year":"2018","unstructured":"Alsebayel MM, Abaalkhail FA, Alsebayel FM, Alissa DA, Al-Jedai AH, Elsiesy H. Congenital esophageal atresia and microtia in a newborn secondary to mycophenolate mofetil exposure during pregnancy: a case report and review of the literature. Am J Case Rep. 2018, 19:523-6. 10.12659\/AJCR.908433","journal-title":"Am J Case Rep"},{"key":"ref176","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.32685","article-title":"Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature","volume":"149A","author":"Anderka MT","year":"2009","unstructured":"Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009, 149A:1241-8. 10.1002\/ajmg.a.32685","journal-title":"Am J Med Genet A"},{"key":"ref177","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.23003","article-title":"Teratogen update: methotrexate","volume":"94","author":"Hyoun SC","year":"2012","unstructured":"Hyoun SC, Obi\u010dan SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012, 94:187-207. 10.1002\/bdra.23003","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"ref178","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A034","article-title":"FDA labeling system for drugs in pregnancy","volume":"35","author":"Boothby LA","year":"2001","unstructured":"Boothby LA, Doering PL. FDA labeling system for drugs in pregnancy. Ann Pharmacother. 2001, 35:1485-9. 10.1345\/aph.1A034","journal-title":"Ann Pharmacother"},{"key":"ref179","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241060-00003","article-title":"Clinical pharmacokinetics of leflunomide","volume":"41","author":"Rozman B","year":"2002","unstructured":"Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2002, 41:421-30. 10.2165\/00003088-200241060-00003","journal-title":"Clin Pharmacokinet"},{"key":"ref180","doi-asserted-by":"publisher","DOI":"10.1002\/art.27358","article-title":"Birth outcomes in women who have taken leflunomide during pregnancy","volume":"62","author":"Chambers CD","year":"2010","unstructured":"Chambers CD, Johnson DL, Robinson LK, et al.. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010, 62:1494-503. 10.1002\/art.27358","journal-title":"Arthritis Rheum"},{"key":"ref181","unstructured":"Cardiovascular diseases. (2023). Accessed. May 3, 2023: https:\/\/www.who.int\/health-topics\/cardiovascular-diseases."},{"key":"ref182","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.307547","article-title":"Cardiovascular disease in women: clinical perspectives","volume":"118","author":"Garcia M","year":"2016","unstructured":"Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016, 118:1273-93. 10.1161\/CIRCRESAHA.116.307547","journal-title":"Circ Res"},{"key":"ref183","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.03.044","article-title":"Cardiovascular and autoimmune diseases in females: the role of microvasculature and dysfunctional endothelium","volume":"241","author":"Gianturco L","year":"2015","unstructured":"Gianturco L, Bodini BD, Atzeni F, et al.. Cardiovascular and autoimmune diseases in females: the role of microvasculature and dysfunctional endothelium. Atherosclerosis. 2015, 241:259-63. 10.1016\/j.atherosclerosis.2015.03.044","journal-title":"Atherosclerosis"},{"key":"ref184","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-009-8192-4","article-title":"The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies","volume":"40","author":"Weckerle CE","year":"2011","unstructured":"Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol. 2011, 40:42-9. 10.1007\/s12016-009-8192-4","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref185","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.112.668319","article-title":"Utility of Framingham Coronary Heart Disease Risk Score for predicting cardiac risk after stroke","volume":"43","author":"Towfighi A","year":"2012","unstructured":"Towfighi A, Markovic D, Ovbiagele B. Utility of Framingham Coronary Heart Disease Risk Score for predicting cardiac risk after stroke. Stroke. 2012, 43:2942-7. 10.1161\/STROKEAHA.112.668319","journal-title":"Stroke"},{"key":"ref186","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.87.2.153","article-title":"Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions","volume":"87","author":"Huo Y","year":"2000","unstructured":"Huo Y, Hafezi-Moghadam A, Ley K. Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circ Res. 2000, 87:153-9. 10.1161\/01.res.87.2.153","journal-title":"Circ Res"},{"key":"ref187","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2015.0803","article-title":"Chronic inflammatory diseases and endothelial dysfunction","volume":"7","author":"Castellon X","year":"2016","unstructured":"Castellon X, Bogdanova V. Chronic inflammatory diseases and endothelial dysfunction. Aging Dis. 2016, 7:81-9. 10.14336\/AD.2015.0803","journal-title":"Aging Dis"},{"key":"ref188","doi-asserted-by":"publisher","DOI":"10.1126\/science.1064890","article-title":"Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus","volume":"294","author":"Blanco P","year":"2001","unstructured":"Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001, 294:1540-3. 10.1126\/science.1064890","journal-title":"Science"},{"key":"ref189","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks JJ","year":"1979","unstructured":"Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979, 301:5-8. 10.1056\/NEJM197907053010102","journal-title":"N Engl J Med"},{"key":"ref190","doi-asserted-by":"publisher","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou KA","year":"2005","unstructured":"Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005, 52:1491-503. 10.1002\/art.21031","journal-title":"Arthritis Rheum"},{"key":"ref191","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1990.tb00144.x","article-title":"Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour","volume":"227","author":"R\u00f6nnblom LE","year":"1990","unstructured":"R\u00f6nnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med. 1990, 227:207-10. 10.1111\/j.1365-2796.1990.tb00144.x","journal-title":"J Intern Med"},{"key":"ref192","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-1024-2","article-title":"Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C","volume":"24","author":"Niewold TB","year":"2005","unstructured":"Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol. 2005, 24:178-81. 10.1007\/s10067-004-1024-2","journal-title":"Clin Rheumatol"},{"key":"ref193","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318177627d","article-title":"Interferon alpha-induced lupus: proof of principle","volume":"14","author":"Niewold TB","year":"2008","unstructured":"Niewold TB. Interferon alpha-induced lupus: proof of principle. J Clin Rheumatol. 2008, 14:131-2. 10.1097\/RHU.0b013e318177627d","journal-title":"J Clin Rheumatol"},{"key":"ref194","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold TB","year":"2007","unstructured":"Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8:492-502. 10.1038\/sj.gene.6364408","journal-title":"Genes Immun"},{"key":"ref195","doi-asserted-by":"publisher","DOI":"10.1002\/art.23619","article-title":"Age- and sex-related patterns of serum interferon-alpha activity in lupus families","volume":"58","author":"Niewold TB","year":"2008","unstructured":"Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum. 2008, 58:2113-9. 10.1002\/art.23619","journal-title":"Arthritis Rheum"},{"key":"ref196","doi-asserted-by":"publisher","DOI":"10.15280\/jlm.2022.12.1.37","article-title":"Lifestyle interventions and weight management in systemic lupus erythematosus patients: a systematic literature review and metanalysis","volume":"12","author":"Goessler KF","year":"2022","unstructured":"Goessler KF, Gualano B, Nonino CB, Bonf\u00e1 E, Nicoletti CF. Lifestyle interventions and weight management in systemic lupus erythematosus patients: a systematic literature review and metanalysis. J Lifestyle Med. 2022, 12:37-46. 10.15280\/jlm.2022.12.1.37","journal-title":"J Lifestyle Med"},{"key":"ref197","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020504","article-title":"The impact of obesity and a high-fat diet on clinical and immunological features in systemic lupus erythematosus","volume":"13","author":"Kono M","year":"2021","unstructured":"Kono M, Nagafuchi Y, Shoda H, Fujio K. The impact of obesity and a high-fat diet on clinical and immunological features in systemic lupus erythematosus. Nutrients. 2021, 13:10.3390\/nu13020504","journal-title":"Nutrients"},{"key":"ref198","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4336-3","article-title":"The impact of obesity on SLE disease activity: findings from the Southern California Lupus Registry (SCOLR)","volume":"38","author":"Teh P","year":"2019","unstructured":"Teh P, Zakhary B, Sandhu VK. The impact of obesity on SLE disease activity: findings from the Southern California Lupus Registry (SCOLR). Clin Rheumatol. 2019, 38:597-600. 10.1007\/s10067-018-4336-3","journal-title":"Clin Rheumatol"},{"key":"ref199","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.12.005","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie JR","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018, 34:575-84. 10.1016\/j.cjca.2017.12.005","journal-title":"Can J Cardiol"},{"key":"ref200","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.3.4.273","article-title":"Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus","volume":"3","author":"Horizon AA","year":"2004","unstructured":"Horizon AA, Wallace DJ. Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin Drug Saf. 2004, 3:273-8. 10.1517\/14740338.3.4.273","journal-title":"Expert Opin Drug Saf"},{"key":"ref201","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126347","article-title":"Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study","volume":"10","author":"Tsai WC","year":"2015","unstructured":"Tsai WC, Ou TT, Yen JH, Wu CC, Tung YC. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015, 10:e0126347. 10.1371\/journal.pone.0126347","journal-title":"PLoS One"},{"key":"ref202","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.860586","article-title":"Lipid metabolism: immune regulation and therapeutic prospectives in systemic lupus erythematosus","volume":"13","author":"Sun W","year":"2022","unstructured":"Sun W, Li P, Cai J, Ma J, Zhang X, Song Y, Liu Y. Lipid metabolism: immune regulation and therapeutic prospectives in systemic lupus erythematosus. Front Immunol. 2022, 13:860586. 10.3389\/fimmu.2022.860586","journal-title":"Front Immunol"},{"key":"ref203","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212902","article-title":"Response to: 'statins in systemic lupus erythematosus' by Abud-Mendoza","volume":"78","author":"de Jong HJ","year":"2019","unstructured":"de Jong HJ, van Staa TP, Cohen Tervaert JW. Response to: 'statins in systemic lupus erythematosus' by Abud-Mendoza. Ann Rheum Dis. 2019, 78:e43. 10.1136\/annrheumdis-2017-212902","journal-title":"Ann Rheum Dis"},{"key":"ref204","doi-asserted-by":"publisher","DOI":"10.1186\/ar1957","article-title":"Anti-inflammatory and immunosuppressive drugs and reproduction","volume":"8","author":"\u00d8stensen M","year":"2006","unstructured":"\u00d8stensen M, Khamashta M, Lockshin M, et al.. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006, 8:209. 10.1186\/ar1957","journal-title":"Arthritis Res Ther"},{"key":"ref205","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2157oa","article-title":"High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk","volume":"14","author":"Barnes EV","year":"2005","unstructured":"Barnes EV, Narain S, Naranjo A, et al.. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus. 2005, 14:576-82. 10.1191\/0961203305lu2157oa","journal-title":"Lupus"},{"key":"ref206","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman MJ","year":"2003","unstructured":"Roman MJ, Shanker BA, Davis A, et al.. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003, 349:2399-406. 10.1056\/NEJMoa035471","journal-title":"N Engl J Med"},{"key":"ref207","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile JM","year":"2001","unstructured":"Esdaile JM, Abrahamowicz M, Grodzicky T, et al.. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001, 44:2331-7. 10.1002\/1529-0131(200110)44:10&lt;2331::aid-art395&gt;3.0.co;2-i","journal-title":"Arthritis Rheum"},{"key":"ref208","article-title":"Natural history of hypercholesterolemia in systemic lupus erythematosus","volume":"26","author":"Bruce IN","year":"1999","unstructured":"Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol. 1999, 26:2137-43.","journal-title":"J Rheumatol"},{"key":"ref209","article-title":"Lipid profiles in patients with systemic lupus erythematosus","volume":"21","author":"Leong KH","year":"1994","unstructured":"Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol. 1994, 21:1264-7.","journal-title":"J Rheumatol"},{"key":"ref210","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312469260","article-title":"Weight change associated with corticosteroid therapy in adolescents with systemic lupus erythematosus","volume":"22","author":"Manaboriboon B","year":"2013","unstructured":"Manaboriboon B, Silverman ED, Homsanit M, Chui H, Kaufman M. Weight change associated with corticosteroid therapy in adolescents with systemic lupus erythematosus. Lupus. 2013, 22:164-70. 10.1177\/0961203312469260","journal-title":"Lupus"},{"key":"ref211","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew231","article-title":"Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study","volume":"55","author":"Iudici M","year":"2016","unstructured":"Iudici M, Fasano S, Gabriele Falcone L, Pantano I, La Montagna G, Migliaresi S, Valentini G. Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology (Oxford). 2016, 55:1623-30. 10.1093\/rheumatology\/kew231","journal-title":"Rheumatology (Oxford)"},{"key":"ref212","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1269168","article-title":"Hydroxychloroquine in systemic lupus erythematosus (SLE)","volume":"16","author":"Ponticelli C","year":"2017","unstructured":"Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017, 16:411-9. 10.1080\/14740338.2017.1269168","journal-title":"Expert Opin Drug Saf"},{"key":"ref213","unstructured":"Systemic lupus erythematosus (SLE). (2022). Accessed. May 3, 2023: https:\/\/emedicine.medscape.com\/article\/332244-overview."},{"key":"ref214","doi-asserted-by":"publisher","DOI":"10.4103\/ijn.IJN_12_18","article-title":"Systemic lupus erythematosus and myasthenia gravis: a rare association","volume":"29","author":"Nagarajan M","year":"2019","unstructured":"Nagarajan M, Maasila AT, Dhanapriya J, et al.. Systemic lupus erythematosus and myasthenia gravis: a rare association. Indian J Nephrol. 2019, 29:62-4. 10.4103\/ijn.IJN_12_18","journal-title":"Indian J Nephrol"},{"key":"ref215","unstructured":"Myasthenia gravis. (2023). Accessed. May 3, 2023: https:\/\/emedicine.medscape.com\/article\/1171206-overview."},{"key":"ref216","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2015.096","article-title":"Systemic lupus erythematosus and secondary antiphospholipid syndrome after thymectomy for myasthenia gravis - a case report","volume":"3","author":"Miskovic R","year":"2015","unstructured":"Miskovic R, Plavsic A, Peric-Popadic A, Raskovic S, Bogic M. Systemic lupus erythematosus and secondary antiphospholipid syndrome after thymectomy for myasthenia gravis - a case report. Open Access Maced J Med Sci. 2015, 3:439-42. 10.3889\/oamjms.2015.096","journal-title":"Open Access Maced J Med Sci"},{"key":"ref217","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.07.007","article-title":"Systemic lupus erythematosus-myasthenia gravis overlap syndrome: presentation and treatment depend on prior thymectomy","volume":"194","author":"Minchenberg SB","year":"2018","unstructured":"Minchenberg SB, Chaparala G, Oaks Z, Banki K, Perl A. Systemic lupus erythematosus-myasthenia gravis overlap syndrome: presentation and treatment depend on prior thymectomy. Clin Immunol. 2018, 194:100-4. 10.1016\/j.clim.2018.07.007","journal-title":"Clin Immunol"},{"key":"ref218","doi-asserted-by":"publisher","DOI":"10.12890\/2014_000020","article-title":"Development of myasthenia gravis in systemic lupus erythematosus","volume":"1","author":"Kigawa N","year":"2014","unstructured":"Kigawa N, Pineau C, Clarke AE, et al.. Development of myasthenia gravis in systemic lupus erythematosus. Eur J Case Rep Intern Med. 2014, 1:10.12890\/2014_000020","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref219","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308093463","article-title":"Myasthenia gravis associated with lupus nephritis","volume":"17","author":"Lee H","year":"2008","unstructured":"Lee H, Chen W, Su K, Chou C, Tsai C. Myasthenia gravis associated with lupus nephritis. Lupus. 2008, 17:860-1. 10.1177\/0961203308093463","journal-title":"Lupus"},{"key":"ref220","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2383","article-title":"The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis","volume":"108","author":"Meraouna A","year":"2006","unstructured":"Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tallaksen C, Berrih-Aknin S. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood. 2006, 108:432-40. 10.1182\/blood-2005-06-2383","journal-title":"Blood"},{"key":"ref221","doi-asserted-by":"publisher","DOI":"10.1007\/BF02602952","article-title":"The role of chemokines in inflammation","volume":"26","author":"Proost P","year":"1996","unstructured":"Proost P, Wuyts A, van Damme J. The role of chemokines in inflammation. Int J Clin Lab Res. 1996, 26:211-23. 10.1007\/BF02602952","journal-title":"Int J Clin Lab Res"},{"key":"ref222","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01265","article-title":"Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update","volume":"10","author":"Lotfi N","year":"2019","unstructured":"Lotfi N, Thome R, Rezaei N, Zhang GX, Rezaei A, Rostami A, Esmaeil N. Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update. Front Immunol. 2019, 10:1265. 10.3389\/fimmu.2019.01265","journal-title":"Front Immunol"},{"key":"ref223","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.773","article-title":"Systemic lupus erythematosus and myasthenia gravis","volume":"119","author":"Hrycek A","year":"2009","unstructured":"Hrycek A. Systemic lupus erythematosus and myasthenia gravis. Pol Arch Med Wewn. 2009, 119:582-5. 10.20452\/pamw.773","journal-title":"Pol Arch Med Wewn"},{"key":"ref224","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6335-z","article-title":"The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature","volume":"259","author":"Jallouli M","year":"2012","unstructured":"Jallouli M, Saadoun D, Eymard B, et al.. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol. 2012, 259:1290-7. 10.1007\/s00415-011-6335-z","journal-title":"J Neurol"},{"key":"ref225","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2004.19.1.134","article-title":"Appearance of systemic lupus erythematosus in patients with myasthenia gravis following thymectomy: two case reports","volume":"19","author":"Park MJ","year":"2004","unstructured":"Park MJ, Kim YA, Lee SS, Kim BC, Kim MK, Cho KH. Appearance of systemic lupus erythematosus in patients with myasthenia gravis following thymectomy: two case reports. J Korean Med Sci. 2004, 19:134-6. 10.3346\/jkms.2004.19.1.134","journal-title":"J Korean Med Sci"},{"key":"ref226","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.110","article-title":"Myasthenia gravis and associated diseases","volume":"6","author":"Tanovska N","year":"2018","unstructured":"Tanovska N, Novotni G, Sazdova-Burneska S, et al.. Myasthenia gravis and associated diseases. Open Access Maced J Med Sci. 2018, 6:472-8. 10.3889\/oamjms.2018.110","journal-title":"Open Access Maced J Med Sci"},{"key":"ref227","doi-asserted-by":"publisher","DOI":"10.1159\/000365568","article-title":"The course of myasthenia gravis with systemic lupus erythematosus","volume":"72","author":"Bekircan-Kurt CE","year":"2014","unstructured":"Bekircan-Kurt CE, Tuncer Kurne A, Erdem-Ozdamar S, Kalyoncu U, Karabudak R, Tan E. The course of myasthenia gravis with systemic lupus erythematosus. Eur Neurol. 2014, 72:326-9. 10.1159\/000365568","journal-title":"Eur Neurol"},{"key":"ref228","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200601000-00004","article-title":"High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study","volume":"331","author":"Sthoeger Z","year":"2006","unstructured":"Sthoeger Z, Neiman A, Elbirt D, et al.. High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study. Am J Med Sci. 2006, 331:4-9. 10.1097\/00000441-200601000-00004","journal-title":"Am J Med Sci"},{"key":"ref229","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon S","year":"2021","unstructured":"Dhillon S. Telitacicept: first approval. Drugs. 2021, 81:1671-5. 10.1007\/s40265-021-01591-1","journal-title":"Drugs"},{"key":"ref230","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan Y","year":"2022","unstructured":"Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today (Barc). 2022, 58:23-32. 10.1358\/dot.2022.58.1.3352743","journal-title":"Drugs Today (Barc)"},{"key":"ref231","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis S","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006, 4:295-306. 10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"},{"key":"ref232","doi-asserted-by":"publisher","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera R","year":"2002","unstructured":"Cervera R, Piette JC, Font J, et al.. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002, 46:1019-27. 10.1002\/art.10187","journal-title":"Arthritis Rheum"},{"key":"ref233","article-title":"Primary antiphospholipid syndrome: functional outcome after 10 years","volume":"27","author":"Erkan D","year":"2000","unstructured":"Erkan D, Yazici Y, Sobel R, Lockshin MD. Primary antiphospholipid syndrome: functional outcome after 10 years. J Rheumatol. 2000, 27:2817-21.","journal-title":"J Rheumatol"},{"key":"ref234","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri M","year":"2000","unstructured":"Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000, 15:145-51. 10.1006\/jaut.2000.0409","journal-title":"J Autoimmun"},{"key":"ref235","doi-asserted-by":"publisher","DOI":"10.1191\/096120300678828226","article-title":"Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort","volume":"9","author":"Petri M","year":"2000","unstructured":"Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus. 2000, 9:170-5. 10.1191\/096120300678828226","journal-title":"Lupus"},{"key":"ref236","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.07.012","article-title":"The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort","volume":"114","author":"Petri M","year":"2004","unstructured":"Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res. 2004, 114:593-5. 10.1016\/j.thromres.2004.07.012","journal-title":"Thromb Res"},{"key":"ref237","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-9-682","article-title":"Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance","volume":"112","author":"Love PE","year":"1990","unstructured":"Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990, 112:682-98. 10.7326\/0003-4819-112-9-682","journal-title":"Ann Intern Med"},{"key":"ref238","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600510","article-title":"Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis","volume":"6","author":"Wahl DG","year":"1997","unstructured":"Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis. Lupus. 1997, 6:467-73. 10.1177\/096120339700600510","journal-title":"Lupus"},{"key":"ref239","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310378669","article-title":"Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia","volume":"19","author":"Al Arfaj AS","year":"2010","unstructured":"Al Arfaj AS, Khalil N. Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia. Lupus. 2010, 19:1665-73. 10.1177\/0961203310378669","journal-title":"Lupus"},{"key":"ref240","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken458","article-title":"Pregnancy outcome in systemic lupus erythematosus complicated by anti-phospholipid antibodies","volume":"48","author":"Mecacci F","year":"2009","unstructured":"Mecacci F, Bianchi B, Pieralli A, et al.. Pregnancy outcome in systemic lupus erythematosus complicated by anti-phospholipid antibodies. Rheumatology (Oxford). 2009, 48:246-9. 10.1093\/rheumatology\/ken458","journal-title":"Rheumatology (Oxford)"},{"key":"ref241","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00240110","article-title":"A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis","volume":"5","author":"Smyth A","year":"2010","unstructured":"Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010, 5:2060-8. 10.2215\/CJN.00240110","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref242","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.028522","article-title":"Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies","volume":"124","author":"Zuily S","year":"2011","unstructured":"Zuily S, Regnault V, Selton-Suty C, et al.. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011, 124:215-24. 10.1161\/CIRCULATIONAHA.111.028522","journal-title":"Circulation"},{"key":"ref243","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0478-8","article-title":"Pulmonary hypertension in antiphospholipid syndrome","volume":"17","author":"Zuily S","year":"2015","unstructured":"Zuily S, Wahl D. Pulmonary hypertension in antiphospholipid syndrome. Curr Rheumatol Rep. 2015, 17:478. 10.1007\/s11926-014-0478-8","journal-title":"Curr Rheumatol Rep"},{"key":"ref244","article-title":"Increased risk of livedo reticularis associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: a systematic review and meta-analysis (Abstract)","volume":"67","author":"DeFlippis E","year":"2015","unstructured":"DeFlippis E, Wahl D, Zuily S. Increased risk of livedo reticularis associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: a systematic review and meta-analysis (Abstract). Arthritis Rheum. 2015, 67:2182 (suppl 10).","journal-title":"Arthritis Rheum"},{"key":"ref245","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2015.0085","article-title":"The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus","volume":"3","author":"\u00dcnl\u00fc O","year":"2016","unstructured":"\u00dcnl\u00fc O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016, 3:75-84. 10.5152\/eurjrheum.2015.0085","journal-title":"Eur J Rheumatol"},{"key":"ref246","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315572717","article-title":"The role of antiphospholipid autoantibodies in the cognitive deficits of patients with systemic lupus erythematosus","volume":"24","author":"Co\u00edn MA","year":"2015","unstructured":"Co\u00edn MA, Vilar-L\u00f3pez R, Peralta-Ram\u00edrez I, Hidalgo-Ruzzante N, Callejas-Rubio JL, Ortego-Centeno N, P\u00e9rez-Garc\u00eda M. The role of antiphospholipid autoantibodies in the cognitive deficits of patients with systemic lupus erythematosus. Lupus. 2015, 24:875-9. 10.1177\/0961203315572717","journal-title":"Lupus"},{"key":"ref247","doi-asserted-by":"publisher","DOI":"10.1177\/0961203306074767","article-title":"Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients","volume":"16","author":"Tarr T","year":"2007","unstructured":"Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus. 2007, 16:39-45. 10.1177\/0961203306074767","journal-title":"Lupus"},{"key":"ref248","doi-asserted-by":"publisher","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou MG","year":"2009","unstructured":"Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009, 61:29-36. 10.1002\/art.24232","journal-title":"Arthritis Rheum"},{"key":"ref249","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307084724","article-title":"Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients","volume":"17","author":"Hereng T","year":"2008","unstructured":"Hereng T, Lambert M, Hachulla E, et al.. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus. 2008, 17:11-5. 10.1177\/0961203307084724","journal-title":"Lupus"},{"key":"ref250","article-title":"[Two cases of systemic lupus erythematosus accompanied by antiphospholipid syndrome nephropathy without immune complex nephritis]","volume":"44","author":"Komiya T","year":"2002","unstructured":"Komiya T, Okamura M, Kawakami K, et al.. [Two cases of systemic lupus erythematosus accompanied by antiphospholipid syndrome nephropathy without immune complex nephritis]. Nihon Jinzo Gakkai Shi. 2002, 44:817-22.","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"ref251","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu461oa","article-title":"Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy","volume":"12","author":"Korkmaz C","year":"2003","unstructured":"Korkmaz C, Kabukcuo\u011flu S, Isiksoy S, Yal\u00e7in AU. Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy. Lupus. 2003, 12:760-5. 10.1191\/0961203303lu461oa","journal-title":"Lupus"},{"key":"ref252","doi-asserted-by":"publisher","DOI":"10.1159\/000027995","article-title":"Massive proteinuria as a main manifestation of primary antiphospholipid syndrome","volume":"66","author":"Levy Y","year":"1998","unstructured":"Levy Y, George J, Ziporen L, et al.. Massive proteinuria as a main manifestation of primary antiphospholipid syndrome. Pathobiology. 1998, 66:49-52. 10.1159\/000027995","journal-title":"Pathobiology"},{"key":"ref253","article-title":"[Low-molecular heparins in the treatment of APS-nephropathy in primary and secondary antiphospholipid syndrome]","volume":"76","author":"Kozlovskaia NL","year":"2004","unstructured":"Kozlovskaia NL, Shakhnova EA, Kushnir VV, Shilov EM. [Low-molecular heparins in the treatment of APS-nephropathy in primary and secondary antiphospholipid syndrome]. Ter Arkh. 2004, 76:35-40.","journal-title":"Ter Arkh"},{"key":"ref254","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias GK","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, et al.. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012, 71:1771-82. 10.1136\/annrheumdis-2012-201940","journal-title":"Ann Rheum Dis"},{"key":"ref255","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud G","year":"2014","unstructured":"Canaud G, Bienaim\u00e9 F, Tabarin F, et al.. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014, 371:303-12. 10.1056\/NEJMoa1312890","journal-title":"N Engl J Med"},{"key":"ref256","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22675","article-title":"Effectiveness of nonpharmacologic interventions for decreasing fatigue in adults with systemic lupus erythematosus: a systematic review","volume":"68","author":"del Pino-Sede\u00f1o T","year":"2016","unstructured":"del Pino-Sede\u00f1o T, Trujillo-Mart\u00edn MM, Ruiz-Irastorza G, Cuellar-Pompa L, de Pascual-Medina AM, Serrano-Aguilar P. Effectiveness of nonpharmacologic interventions for decreasing fatigue in adults with systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2016, 68:141-8. 10.1002\/acr.22675","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref257","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000441","article-title":"Towards a practical management of fatigue in systemic lupus erythematosus","volume":"7","author":"Mertz P","year":"2020","unstructured":"Mertz P, Schlencker A, Schneider M, Gavand PE, Martin T, Arnaud L. Towards a practical management of fatigue in systemic lupus erythematosus. Lupus Sci Med. 2020, 7:10.1136\/lupus-2020-000441","journal-title":"Lupus Sci Med"},{"key":"ref258","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13046","article-title":"Balneotherapy, a complementary non-pharmacological approach for non-inflammatory complaints in systemic lupus erythematosus: a pilot study","volume":"36","author":"Fritsch K","year":"2022","unstructured":"Fritsch K, Nagy G, Szekanecz Z, Sz\u0171cs G, Kovacs L, Bender T. Balneotherapy, a complementary non-pharmacological approach for non-inflammatory complaints in systemic lupus erythematosus: a pilot study. In Vivo. 2022, 36:3010-7. 10.21873\/invivo.13046","journal-title":"In Vivo"},{"key":"ref259","doi-asserted-by":"publisher","DOI":"10.1186\/s43088-021-00185-w","article-title":"Effect of training on health outcome including fatigue, depression and quality of life in patients with systemic lupus erythromatosus","volume":"10","author":"Youssef MK","year":"2021","unstructured":"Youssef MK. Effect of training on health outcome including fatigue, depression and quality of life in patients with systemic lupus erythromatosus. Beni-Suef Univ J Basic Appl Sci. 2021, 10:90. 10.1186\/s43088-021-00185-w","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"key":"ref260","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejr.2022.04.001","article-title":"Impact of psycho-educational therapy on disease activity, quality of life, psychological status, treatment satisfaction and adherence in systemic lupus erythematosus patients","volume":"44","author":"Sakr BR","year":"2022","unstructured":"Sakr BR, Seif EM, Kamel RM, Eleishi HH. Impact of psycho-educational therapy on disease activity, quality of life, psychological status, treatment satisfaction and adherence in systemic lupus erythematosus patients. Egypt Rheumatol. 2022, 44:313-7. 10.1016\/j.ejr.2022.04.001","journal-title":"Egypt Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/162942-a-comprehensive-literature-review-on-managing-systemic-lupus-erythematosus-addressing-cardiovascular-disease-risk-in-females-and-its-autoimmune-disease-associations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:38Z","timestamp":1707509018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/162942-a-comprehensive-literature-review-on-managing-systemic-lupus-erythematosus-addressing-cardiovascular-disease-risk-in-females-and-its-autoimmune-disease-associations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":260,"URL":"https:\/\/doi.org\/10.7759\/cureus.43725","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,18]]}}}